Download the app
App StorePlay Store
Beige
Login
← All tags

drug pricing

Bayer to push harder on tiered pricing for its drugs in India

Bayer to push harder on tiered pricing for its drugs in India

In an exclusive interview, Bayer’s global head of pharmaceuticals, Stefan Oelrich, said the company will intensify its push for tiered pricing in India. The move is linked to Bayer’s “tailormade India” portfolio and its broader investment plans in innovation, aiming to balance affordability with business sustainability.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Semaglutide API prices tumble as GLP-1 demand surges and generics flood markets

Semaglutide API prices tumble as GLP-1 demand surges and generics flood markets

Semaglutide API prices are falling sharply as global demand for weight-loss drugs like Ozempic and Wegovy drives rapid manufacturing expansion. With patents set to expire in key markets and Indian companies rolling out lower-priced generics, analysts expect additional price softening. The shift could widen access to these GLP-1 therapies for patients in the months ahead.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Your news, in seconds

App StorePlay Store
Patients voice enters drug pricing reform committee expanding for faster fairer outcomes

Patients voice enters drug pricing reform committee expanding for faster fairer outcomes

A key committee reviewing India’s drug pricing reforms has been expanded to include patients, shifting the debate from numbers on paper to real healthcare impact. The move aims to make pricing decisions more grounded in affordability and access, potentially influencing how reforms are designed and implemented as stakeholders push for faster, fairer outcomes.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Mounjaro sales dip in India as Ozempic price cuts and semaglutide generics surge

Mounjaro sales dip in India as Ozempic price cuts and semaglutide generics surge

Mounjaro sales are sliding across India as Novo Nordisk drives a price war for Ozempic and Wegovy and cheaper semaglutide generics gain traction. Eli Lilly says it’s seeing increased competition but remains confident in Mounjaro’s differentiated benefits for users. The shift highlights how rapidly GLP-1 therapy markets are being reshaped by pricing pressure.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
US market prospects for Indian pharma brighten as shortages and new generics reshape profits

US market prospects for Indian pharma brighten as shortages and new generics reshape profits

Indian pharma’s US outlook has improved after years of pressure from price erosion and compliance hurdles. Drug shortages have temporarily slowed price erosion, while launches of key generic drugs have helped companies regain footing. Yet the real question is sustainability: will the same conditions hold, or will competition and supply normalization bring renewed margin stress?

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Trump announces Regeneron deal to cut Medicaid prices and slash Praluent cost

Trump announces Regeneron deal to cut Medicaid prices and slash Praluent cost

Trump has unveiled a deal with Regeneron aimed at lowering US healthcare costs under the most-favored-nation push. The company will cut prices for its drugs on Medicaid, and Praluent, a cholesterol medicine, is set to be sold for $225 on Trump’s discounted drug website. Regeneron also pledges major investment in US research and development.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Never miss a story

App StorePlay Store
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play